Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
LATS1
REST API REST API
Homo sapiens
LATS1 is differentially expressed in 196 experiments: 92 organism parts: blood, bone marrow, ... (90 more);, 115 disease states: normal, control, ... (113 more);, 57 cell types 244 cell lines 27 compound treatments and 76 other conditions.
Synonyms WARTS
Orthologs LATS1 (Bos taurus)   LATS1 (Gallus gallus)   F1M2K4_RAT (Rattus norvegicus)   Lats1 (Mus musculus)   ENSCING00000004083 (Ciona intestinalis)   lats1 (Danio rerio)   wts (Drosophila melanogaster)   ENSCING00000014642 (Ciona intestinalis)   Q07G23_XENTR (Xenopus laevis)   NP_001019806.1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term spindle pole, cell division, sister chromatid segregation, protein binding, cytoskeleton, cytoplasm, hormone-mediated signaling pathway, protein tyrosine kinase activity, ATP binding, cell cycle, magnesium ion binding, microtubule organizing center, protein kinase binding, G2/M transition of mitotic cell cycle, mitosis, nucleotide binding, protein serine/threonine kinase activity, regulation of actin filament polymerization, negative regulation of cyclin-dependent protein kinase activity, protein kinase activity, positive regulation of peptidyl-serine phosphorylation, keratinocyte differentiation, cellular protein localization, cytoplasmic sequestering of protein, regulation of protein complex assembly, hippo signaling cascade, negative regulation of canonical Wnt receptor signaling pathway, protein phosphorylation
InterPro Term UBA/transl_elong_EF1B_N_euk, UBA/transl_elong_EF1B_N, Pkinase_C, Prot_kinase_cat_dom, Ser/Thr_kinase_dom, Tyr_kinase_cat_dom, Ser-Thr/Tyr_kinase, Se/Thr_kinase-like_dom
UniProt Accession O95835, Q6PJG3
Search EB-eye ENSG00000131023
Show more properties
Experimental Factors
Organism part

studied in E-AFMX-5, E-GEOD-6573, E-MTAB-24, E-MTAB-25, E-GEOD-6919, ... (19 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-2450, E-MTAB-62, ... (26 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-20081, E-GEOD-19639, E-GEOD-5823
A549
2
E-GEOD-3202, E-GEOD-6013
PC3
2
E-GEOD-14464, E-MEXP-2034
primary culture
2
E-GEOD-2450, E-GEOD-1657
CHL1
1
E-MTAB-37
SW1573
1
E-MTAB-37
238 more value(s).


Cell type

studied in E-GEOD-22373, E-GEOD-3920, E-GEOD-20677, E-GEOD-4219, E-GEOD-13987, ... (28 experiments)

Factor Value U/D Experiments
1
2
E-TABM-130, E-TABM-145
CD34+CD38-/lowCD19+ cell
1
1
E-MEXP-1403
leydig cell
1
E-MTAB-25
articular cartilage
1
E-MEXP-2488
spheroid recovery
1
E-GEOD-4219
adipose stem cells derived from adult human donor
1
E-GEOD-20033
51 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-GEOD-15960, E-MEXP-2069, E-MEXP-1121, ... (39 experiments)

Factor Value U/D Experiments
control
3
E-GEOD-21912, E-GEOD-8121, E-GEOD-16363
lung adenocarcinoma
2
E-MTAB-62, E-MTAB-37
prostate carcinoma
2
E-MEXP-2034, E-MTAB-62
erythroleukemia
1
E-MTAB-37
pancreatic carcinoma
1
E-MEXP-1121
asymptomatic HIV-1 infection
1
E-GEOD-16363
109 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-15205, E-GEOD-5824, E-TABM-868, E-GEOD-15811, ... (14 experiments)

Factor Value U/D Experiments
none
4
E-GEOD-5824, E-MEXP-1958, E-TABM-868, E-GEOD-20719
lipopolysaccharide
2
E-MEXP-1958, E-TABM-868
dimethyl sulfoxide
1
E-GEOD-5824
sapphyrin PCI-2052
1
E-GEOD-6400
unknown
1
E-GEOD-7307
glucose
1
E-MEXP-941
21 more value(s).


Age years

studied in E-TABM-783

Factor Value U/D Experiments
n/a
1
1
E-TABM-783
1
1
E-TABM-783


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-GEOD-4619, E-GEOD-21589, ... (6 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-GEOD-6236, E-GEOD-2666, E-MTAB-62 ... (5 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743

Environmental stress
studied in E-GEOD-1643

Er
studied in E-GEOD-20194, E-GEOD-16716

Er ihc
studied in E-GEOD-21653

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-GEOD-7011, E-MTAB-73, E-MEXP-1482, E-GEOD-20847, ... (7 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-17476, E-TABM-868, E-TABM-601, E-GEOD-17347, ... (6 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-5681, E-MEXP-2657, E-TABM-127, E-GEOD-20540, ... (7 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-974, E-MEXP-2069, E-TABM-26, ... (25 experiments)

Infection
studied in E-GEOD-2405, E-MEXP-561

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Localisation of metastases
studied in E-GEOD-22541

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-21750, E-GEOD-1657, E-GEOD-17636, E-MEXP-1403

Population
studied in E-MTAB-197, E-GEOD-4922

Pr ihc
studied in E-GEOD-21653

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-10896

RNAi
studied in E-MEXP-101, E-GEOD-3697, E-MEXP-1857, E-MEXP-2759

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

Sample type
studied in E-TABM-783

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374, E-GEOD-17400, E-GEOD-18995 ... (5 experiments)

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-GEOD-19246

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.341 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM